Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-5609 in advanced solid tumors
NCT04247126Phase 1Completed
- Sponsor
- Syros Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sy-5609 in solid tumor (advanced stage), Hormone-Receptor-Positive Breast Cancer and pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity at 28 days, Treatment Emergent Adverse Events at 1 year and 1 more. Started Jan 2020; status: completed.
02
Drugs
sy-5609
03
Conditions
solid tumor (advanced stage)Hormone-Receptor-Positive Breast Cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04247126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247126.